Myocardial Ischemia

14
Pipeline Programs
10
Companies
15
Clinical Trials
1 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
9
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 13 programs with unclassified modality

On Market (3)

Approved therapies currently available

U
ASPRUZYO SPRINKLEApproved
ranolazine
Unknown Company
Anti-anginal [EPC]oral2022
U
RANOLAZINEApproved
ranolazine
Unknown Company
Anti-anginal [EPC]oral2020
U
VOSTALLYApproved
ramipril
Unknown Company
Angiotensin Converting Enzyme Inhibitor [EPC]oral2025

Competitive Landscape

10 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
2 programs
1
1
RanolazinePhase 41 trial
RanolazinePhase 31 trial
Active Trials
NCT00099788Completed6,560Est. Feb 2007
NCT02423265Withdrawn0Est. Mar 2017
GH
2 programs
1
1
Intensive medical therapyPhase 3
RegadenosonPhase 1/21 trial
Active Trials
NCT04604782Recruiting54Est. Dec 2026
Sanofi
SanofiPARIS, France
2 programs
2
Intensive medical therapyPhase 3
RamiprilPhase 3Small Molecule1 trial
Active Trials
NCT00268619Completed
Astellas
AstellasChina - Shenyang
1 program
1
Intensive medical therapyPhase 3
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
Intensive medical therapyPhase 3
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Intensive medical therapyPhase 3
Bristol Myers Squibb
1 program
1
Intensive medical therapyPhase 31 trial
Active Trials
NCT00007657Completed3,260Est. Jun 2006
Pfizer
PfizerNEW YORK, NY
1 program
1
Intensive medical therapyPhase 3
Bayer
BayerLEVERKUSEN, Germany
2 programs
Myocardial CT perfusionN/A1 trial
Stress cardiac magnetic resonanceN/A1 trial
Active Trials
NCT02161081Completed120Est. Jul 2014
NCT03192891Completed2,349Est. Nov 2019
Abbott
AbbottABBOTT PARK, IL
1 program
ABSORB BVSN/A5 trials
Active Trials
NCT02943616Withdrawn0Est. Jan 2021
NCT02928198Unknown3Est. Mar 2020
NCT02173379Completed2,604Est. Apr 2022
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Gilead SciencesRanolazine
Gilead SciencesRanolazine
SanofiRamipril
Bristol Myers SquibbIntensive medical therapy
GE HealthCareRegadenoson
AbbottABSORB BVS
BayerStress cardiac magnetic resonance
AbbottABSORB BVS
AbbottABSORB BVS
AbbottABSORB BVS
AbbottABSORB BVS
AbbottABSORB BVS
AbbottABSORB BVS
BayerMyocardial CT perfusion
AbbottABSORB BVS

Clinical Trials (15)

Total enrollment: 20,484 patients across 15 trials

NCT02423265Gilead SciencesRanolazine

Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries

Start: Jun 2015Est. completion: Mar 20170
Phase 4Withdrawn
NCT00099788Gilead SciencesRanolazine

Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes

Start: Oct 2004Est. completion: Feb 20076,560 patients
Phase 3Completed
NCT00268619SanofiRamipril

FOCUS:Focus On Coronary Unstable Syndromes

Start: Jun 2004
Phase 3Completed
NCT00007657Bristol Myers SquibbIntensive medical therapy

Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation

Start: Dec 1998Est. completion: Jun 20063,260 patients
Phase 3Completed
NCT04604782GE HealthCareRegadenoson

A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

Start: May 2021Est. completion: Dec 202654 patients
Phase 1/2Recruiting
NCT02943616AbbottABSORB BVS

ABSORB Post-Approval Clinical Study

Start: Aug 2017Est. completion: Jan 20210
N/AWithdrawn
NCT03192891BayerStress cardiac magnetic resonance

Stress CMR Perfusion Imaging in the United States (SPINS) Study

Start: Dec 2016Est. completion: Nov 20192,349 patients
N/ACompleted
NCT02928198AbbottABSORB BVS

Bifurcation ABSORB OCT Trial

Start: Jun 2016Est. completion: Mar 20203 patients
N/AUnknown
NCT02173379AbbottABSORB BVS

Absorb IV Randomized Controlled Trial

Start: Jul 2014Est. completion: Apr 20222,604 patients
N/ACompleted
NCT02171065AbbottABSORB BVS

PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.

Start: Jun 2014Est. completion: May 2020902 patients
N/ACompleted
NCT02229864AbbottABSORB BVS

Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions

Start: May 2014Est. completion: Oct 201912 patients
N/ACompleted
NCT01759290AbbottABSORB BVS

ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.

Start: Jan 2013Est. completion: Dec 20151,800 patients
N/ACompleted
NCT01751906AbbottABSORB BVS

ABSORB III Randomized Controlled Trial (RCT)

Start: Dec 2012Est. completion: Oct 20202,008 patients
N/ACompleted
NCT02161081BayerMyocardial CT perfusion

A Study on Improved Dynamic Myocardial Perfusion With Less Effective Radiation Dose in CT (SIMPLE CT)

Start: Jan 2012Est. completion: Jul 2014120 patients
N/ACompleted
NCT01023789AbbottABSORB BVS

ABSORB EXTEND Clinical Investigation

Start: Jan 2010Est. completion: Oct 2016812 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 20,484 patients
10 companies competing in this space